Testosterone and Erectile Function: A Review of Evidence from Basic Research by Kataoka, Tomoya & Kimura, Kazunori
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 11
Testosterone and Erectile Function: A Review of
Evidence from Basic Research
Tomoya Kataoka and Kazunori Kimura
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/intechopen.72935
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited. 
Tomoya Kataoka and Kazunori Kimura
Additional information is available at the end of the chapter
Abstract
Androgens are essential for male physical activity and normal erectile function. Hence, 
age-related testosterone deficiency, known as late-onset hypogonadism (LOH), is consid-
ered a risk factor for erectile dysfunction (ED). This chapter summarizes relevant basic 
research reports examining the effects of testosterone on erectile function. Testosterone 
affects several organs and is especially active on the erectile tissue. The mechanism of 
testosterone deficiency effects on erectile function and the results of testosterone replace-
ment therapy (TRT) have been well studied. Testosterone affects nitric oxide (NO) pro-
duction and phosphodiesterase type 5 (PDE-5) expression in the corpus cavernosum 
through molecular pathways, preserves smooth muscle contractility by regulating 
both contraction and relaxation, and maintains the structure of the corpus cavernosum. 
Interestingly, testosterone deficiency has relationship to neurological diseases, which 
leads to ED. Testosterone replacement therapy is widely used to treat patients with tes-
tosterone deficiency; however, this treatment might also induce some problems. Basic 
research suggests that PDE-5 inhibitors, L-citrulline, and/or resveratrol therapy might 
be effective therapeutic options for testosterone deficiency-induced ED. Future research 
should confirm these findings through more specific experiments using molecular tools 
and may shed more light on endocrine-related ED and its possible treatments.
Keywords: testosterone, erectile dysfunction, endothelial function, testosterone 
replacement therapy, basic science
1. Introduction
Androgens are essential for male physical activity and normal erectile function [1–5]. Thus, age-
related androgen deficiency, known as late-onset hypogonadism (LOH), is a risk factor for erec-
tile dysfunction (ED) [1, 2]. Several studies have reported that androgen replacement therapy 
mitigates the symptoms of LOH and ED. In this context, bioidentical or synthetic testosterone 
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facilitates erectile function by maintaining an adequate supply of nitric oxide (NO), penile struc-
ture, and the endothelial functioning of the corpus cavernosum. Thus, reduced NO bioavailability 
is believed to be the main cause of ED in individuals with testosterone deficiency [6]; however, 
the pathophysiological mechanisms underlying this process remain unclear and require further 
study. This chapter summarizes relevant basic research reports examining the effects of testoster-
one on erectile function.
2. Testosterone and erectile function
Androgens are well established as being essential for erectile function, and their deficiency 
is considered a risk factor for ED. LOH is a result of the normal aging process and is respon-
sible for androgen deficiency [7, 8]. In recent years, epidemiologic studies have suggested 
that metabolic syndrome and diabetes mellitus are also associated with the development of 
androgen deficiency [9–12].
Erectile function is regulated by complex mechanisms [13]. When sexual stimulation occurs, 
NO is released in the penis, causing corporal smooth muscle relaxation through the activa-
tion of the cGMP/protein kinase G signaling cascade. ED results when the relaxant system is 
weakened; therefore, many studies have focused on smooth muscle relaxation. In contrast, in 
the flaccid state, corporal smooth muscle contraction is controlled by constrictors such as nor-
adrenaline. Recent studies have indicated that the balance between smooth muscle relaxation 
and contraction is disturbed by abnormal activation of the RhoA/Rho-kinase signaling path-
way. In some syndromes causing ED, such as diabetes mellitus or metabolic syndrome, the 
RhoA/Rho-kinase signaling pathway is enhanced [14–16]. Additionally, enhancement of the 
RhoA/Rho-kinase signaling pathway is known to occur in aged individuals, and a Rho-kinase 
inhibitor (Y-27632) has been shown to improve erectile function in aged rats [17, 18]. As con-
tractility may play a significant role in erectile function, its role in ED should be considered 
along with contraction. Thus, the balance between smooth muscle contraction and relaxation 
is important for normal erectile function.
3. Testosterone deficiency and ED
Most animal studies have shown that castration causes ED by reducing arterial inflow [19]. 
Further, endothelial nitric oxide synthase (eNOS) and neuronal NOS (nNOS) are important 
in erectile functioning. In castrated animals, testosterone administration restores the erectile 
response and NOS expression in the penis [20]. Li et al. showed that testosterone deficiency 
decreases eNOS activity (phosphor-eNOS/eNOS ratio) by upregulating reactive oxygen spe-
cies production [21], and the decreased eNOS activity decreases cGMP levels in the penis.
Some studies found that testosterone changes phosphodiesterase type 5 (PDE-5) expression 
in the penis. Traish et al. showed that castration decreased PDE-5 activity in rabbit penises 
[22], whereas Zhang et al. showed that testosterone deficiency decreased PDE-5 expression 
in the rat penis and that testosterone administration increased PDE-5 expression [23]. These 
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results suggest that testosterone is essential not only for regulating eNOS activity but also 
for regulating PDE-5 activity. Traish et al. also suggested that while these actions may seem 
paradoxical, in which androgens are upregulating both signal initiators (NOS) and signal 
terminators (PDE-5), they may be interpreted to be part of a homeostatic mechanism that 
maintains a relatively constant ratio of critical pathway enzymes [3]. They also postulated that 
PDE-5 expression may be controlled by NO. Androgen-mediated upregulation of NOS may 
lead to increased NO synthesis, which may then upregulate PDE-5 expression and activity. 
Conversely, androgen deprivation-mediated NOS downregulation also results in the down-
regulation of PDE-5 expression and activity. More studies are needed to define this delicate 
and crucial mechanism of testosterone action.
Testosterone also affects the smooth muscle of the corpus cavernosum. Reilly et al. showed 
that castration reduced the number of α-adrenergic-1 receptors on smooth fascia [24]. They 
also showed that testosterone modulated the adrenergic response of the corpus cavernosum 
vascular smooth muscle [25]. Their results indicate that when testosterone levels decrease, 
smooth muscle contractility also decreases. On the other hand, Wingard et al. showed that 
castration increased the levels of Rho-A and Rho-kinase proteins in rats. RhoA, a small mono-
meric GTPase, activates the Rho-associated protein kinase, a serine/threonine kinase, which 
phosphorylates the myosin-binding subunit of myosin light chain phosphatase, thereby deac-
tivating it and promoting contraction [26]. Their results indicate that when testosterone levels 
decline, smooth muscle contractility increases, leading not only to the development of ED but 
also to the hypertension. Thus, although testosterone deficiency might increase contraction, 
additional research is required to fully elucidate its impact on smooth muscle contraction.
Interestingly, testosterone also directly affects smooth muscle relaxation. Yue et al., using 
an isometric tension study, showed that testosterone relaxed the smooth muscle of rabbit 
coronary arteries and aortas [27]. Others also showed that testosterone induces the relaxation 
of isolated human corpora cavernosa strips by activating smooth muscle ATP-sensitive K+ 
channels [28]. These findings suggest that testosterone, in addition to its known endothe-
lial action, might regulate erectile function locally by acting on human corpus cavernosum 
smooth muscle. These results indicate that testosterone might affect both the genomic and 
nongenomic actions of erectile function.
Some studies demonstrated that testosterone also impacts the structure of the penis. One 
group showed that castrated rats show smooth muscle loss and fibrosis [29], and another 
group reported that castration increases the collagen content of the internal pudendal arter-
ies and decreases α-actin expression [30]. These testosterone effects suggest that testoster-
one deprivation results in programmed trabecular smooth muscle cell death (apoptosis) and 
increased development of extracellular matrix [22]. Traish et al. also proposed that testos-
terone deprivation is associated with the accumulation of fat-containing cells (fibroblasts or 
preadipocyte-like cells), especially in the subtunical region of the corpus cavernosum, con-
tributing to impaired veno-occlusion [31]. Interestingly, Wang et al. showed that castration 
attenuates erectile function and induces corporeal fibrosis by inhibiting autophagy and pro-
moting apoptosis of the corpus cavernosum smooth muscle cells in rats [32]. Their study has 
limitations, but they highlighted the important role of androgens in maintaining the structural 
integrity and functioning of the corpus cavernosum. This resulted from androgens mediating 
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the counter-regulation of autophagy and apoptosis through regulation of the BECN 1-Bcl-2 
(key dual regulators of autophagy and apoptosis) interaction [33, 34].
4. Testosterone and neurogenic factors
ED has relationships between not only cardiovascular diseases but also neurological diseases. 
Yang et al. found the hazard risk for Alzheimer’s disease and non-Alzheimer dementia to be 
greater in patients with ED [35]. They also found that log-rank test revealed that patients with 
ED had significantly higher cumulative incidence rates of dementia than those without. Yang 
et al. found the incidence density rate of Parkinson’s disease (PD) was higher in the ED cohort 
than in the non-ED cohort [36]. Balsamo et al. reported that men with multiple sclerosis had 
high risk of ED [37]. Interestingly, testosterone deficiency is often observed in these neuro-
logical disease patients relative to age-matched controls [38–40].
In basic study, there are some reports on the relationship between testosterone deficiency and 
neurogenic factors. Baba et al. reported the mean number of NOS-containing nerve fibers in 
the corpora cavernosa and in both dorsal nerves of castrated rats [41]. Others also showed 
that castration decreased nNOS protein expression in the corpus cavernosum [32]. However, 
reports regarding nNOS responses differ significantly; some studies show increased activity 
but no change in protein expression [42] in rats, whereas others report no effects in rabbits 
[43]. Thus, more research into the relationship between nNOS and testosterone is required.
On the other hand, Suzuki et al. measured the ICP during electrical stimulation of the pre-
optic area and cavernous nerve in castrated male rats with and without testosterone replace-
ment [44]. They showed the actions of testosterone and its metabolites on both the central and 
peripheral neural pathways are crucial for maintaining and restoring erectile capacity. Syme 
et al. reported that castration resulted in a decreased erectile response to electrostimulation 
following nerve grafting due to decreased graft neuronal nitric oxide synthase-positive axo-
nal regeneration [45]. Armagan et al. indicated that testosterone had a neuroprotective role 
in the nerve fibers of the dorsal nerve and testosterone deficiency led to different forms of 
nerve degeneration resulting in anatomic alterations [46]. Baba et al. also reported that cas-
tration decreased the number of nicotinamide adenine dinucleotide phosphate diaphorase-
staining nerve fibers not only in corpus cavernosum but also in dorsal nerve [47]. These 
results indicate that testosterone deficiency would cause neurogenic dysfunction of erectile 
tissues; however, future study needs to unravel the mechanism of testosterone action to the 
nerve systems.
5. Testosterone and metabolic syndrome
Obesity has become a major public health issue that is associated with increased mortal-
ity primarily due to increased risks of cardiovascular disease and type 2 diabetes mellitus 
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(T2DM) [1, 48, 49]. Obesity is also considered a strong risk factor for ED [4, 5]. In men, visceral 
adipose tissue causes arteriosclerosis and vessel endothelial dysfunction [12]. Therefore, men 
with T2DM have a high incidence of ED [5, 48, 50, 51].
In recent years, epidemiologic studies have suggested that obesity is also associated with 
multiple alterations in the gonadal endocrine system, including low testosterone levels [1, 48, 
52, 53]. Low testosterone levels have also been reported in animals with T2DM, including two 
seminal research papers that reported testosterone replacement therapy (TRT) in such animal 
models [54, 55]. Davis et al. administered TRT to obese Zucker rats, resulting in improved 
cholesterol parameters and insulin sensitivity [54]. On the other hand, others administered 
TRT to rabbits with high-fat diet-associated hypogonadotropic hypogonadism [55]. TRT par-
tially ameliorated the animals’ blood glucose levels and improved CC sensitivity to acetyl-
choline and eNOS.
We also reported that T2DM increased inflammatory biomarker (inducible NO synthase, 
interleukin-6, and tumor necrosis factor alpha) mRNA expression levels in the CC, but 
TRT decreased them [56]. Ota et al. reported an in vitro study that demonstrated tes-
tosterone prevented inflammation caused by hydrogen peroxide in blood vessel cells by 
upregulating the sirtuin-1 (Sirt1)/eNOS pathway [57, 58]. In one of our studies, testoster-
one administration upregulated Sirt1 and eNOS mRNA transcription, possibly prevent-
ing CC inflammation in T2DM rats (Figures 1 and 2). Interestingly, serum asymmetric 
dimethylarginine (ADMA) levels were also increased in T2DM rats, and rats receiving 
TRT were observed to have decreased ADMA levels. ADMA is an endogenous arginine 
compound that rises in individuals demonstrating some disease states [59]; in particular, 
several reports have suggested a potential relationship between ADMA levels and ED [60, 
61]. ADMA has NOS inhibitory activity, and the elevation of ADMA levels contributes to 
decreased NO bioactivity and decreased endothelial functioning of vessel tissues. Zhang 
Figure 1. The mechanism of erectile dysfunction caused by T2DM.
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et al. also reported that testosterone treatment improved nNOS activity using streptozoto-
cin-induced diabetic rat [62].
6. TRT limitations
TRT is widely used to effectively treat patients with testosterone deficiencies. It has also been 
applied to animal models for investigating the mechanisms of testosterone action. However, 
Burns-Cox et al. pointed out that testosterone (testosterone enanthate) injections cause 
extremely high levels of testosterone after a few days [63]. Similarly, we injected testosterone 
enanthate into rats, and the animals demonstrated serum testosterone level increases that rose 
in a dose-dependent manner (Figure 3).
Amano et al. reported that the therapeutic administration of testosterone ointment to patients 
with LOH successfully kept testosterone at normal levels [64]. We administered low-dose tes-
tosterone (similar to applying testosterone ointment) to rats, as previous report [65], 4 weeks 
after castration. Interestingly, this TRT did not improve erectile functioning over the first 
4 weeks of administration. However, after 8 weeks of TRT, partial ED improvements were 
observed (Figure 4). Baba et al. reported that delayed TRT improved ED, in rats, for 4 weeks 
[41]. However, they used high-dose testosterone administrations and the testosterone lev-
els were ≥10 times normal. These results suggest that low-dose testosterone treatments may 
require longer treatment periods to overcome testosterone deficiency. Currently, testoster-
one undecanoate, a drug that is applied over a long period (about 3 months), is widely used 
in European countries. The medication has been shown to be a safe and effective treatment 
for patients with testosterone deficiencies [66]. However, some countries have not approved 
Figure 2. The mechanism of ART for T2DM.
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the medication, and there are no basic science reports addressing its use. These results dem-
onstrate the need to investigate differences between various testosterone administration 
methods.
Erectile functioning is a complex process, with an underlying mechanism that is affected by 
several factors [4, 67–69]. Recent studies have suggested that one of these factors may be 
endogenous estrogen levels [70–77]. For example, Baser et al. suggested that serum estrogen 
levels are correlated with aging in men and that estrogen may, therefore, play an impor-
tant role in the expression of the symptoms of aging [70]. Further, Greco et al. reported that 
tadalafil treatment suppresses estrogen levels in some obese men and improved their erectile 
function domain scores [71]. Another group reported high estrogen levels in elderly patients 
with ED and sexual disinterest; therefore, they suggested that pathophysiological estrogen-
testosterone imbalance is involved in these conditions among elderly men [72, 73]. In a basic 
study, Goyal et al. reported that estrogen caused developmental disorders of the rat penis 
and that it decreased penile testosterone levels [74, 75]. Others reported that estrogen caused 
pathophysiological changes in the corpus cavernosum and a decline in erectile function in 
rats [76]. These authors also reported that estrogen induction enhanced corpus caverno-
sum smooth muscle contraction and decreased smooth muscle relaxation in rabbits [77]. We 
reported the use of TRT in a rat model of testosterone deficiency induced by estrogen injec-
tions. Interestingly, TRT is not an effective ED treatment in the high-estrogen level model [78]. 
Thus, attention needs to be given not only to the testosterone levels but also to the levels of 
other hormones.
Figure 3. Testosterone levels after testosterone injection in rat.
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7. New approaches for testosterone deficiency treatment
Although TRT is an effective treatment for testosterone deficiency, some reports have reported 
a new treatment approach based on the use of testosterone deficiency models that consider 
the mechanism of testosterone action on erectile function. PDE-5 inhibitors are the first choice 
for ED patients, but they are not always effective in patients with testosterone deficiencies 
[79, 80]. One of the reasons for the lack of efficacy might be the PDE-5 expression changes 
induced by testosterone. A combination therapy involving both testosterone and PDE-5 
inhibitors is one choice, but it is the one that is being vigorously debated, with strong reasons 
being presented for and against its use. PDE-5 inhibitors are also effective, but regardless of 
their pharmacokinetics or the regimen used, none has been shown to cure ED [2].
Moody et al. showed that L-arginine administration also improves ED in castrated rats [81]. 
Similarly, we demonstrated that L-citrulline supplementation improves erectile function 
and penile structure in castrated rats [82]. L-arginine and L-citrulline are amino acids pres-
ent in free form in the human body. When L-citrulline is orally administered, it is converted 
to L-argininosuccinate and, subsequently, to L-arginine by renal argininosuccinate lyase [83]. 
L-arginine is then converted to NO and L-citrulline by NOS [84]. Orally administered L-arginine 
is known to be extensively metabolized by autochthonous gut bacteria and by arginases in the 
Figure 4. Different effects of TRT periods for delayed treatment.
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gut and liver [3]. However, oral L-citrulline administrations were shown to avoid such metab-
olism [85]. Accordingly, oral L-citrulline supplementation was reported to increase L-arginine 
levels more efficiently than oral L-arginine administration; L-citrulline also increased NO pro-
duction [86]. In addition, we conducted a similar study using an acute arteriogenic ED model 
[87]. In that study, oral L-citrulline supplementation improved erectile function and increased 
NO production, without side effects (e.g., decreased mean arterial pressure) [87].
Fukuhara et al. showed that resveratrol and vardenafil improved erectile responses in rats 
with streptozotocin-induced diabetes [88]. Recently, Dalaklioglu et al. also reported that res-
veratrol improved sildenafil-induced corpus cavernosum relaxation in both diabetic and non-
diabetic aged rats, probably by potentiating NOS activity [89]. Oral supplementation might 
improve the vasculogenic condition, considering our previous study, though this is just spec-
ulation and needs to be examined.
8. Conclusions
Testosterone levels affect several organs, including the functioning of male erectile tissue. Many 
studies have described the mechanism of testosterone deficiency effects on erectile function as 
well as the impact of TRT. Testosterone affects NO production and PDE-5 expression in the cor-
pus cavernosum through molecular pathways. It also preserves smooth muscle contractility by 
regulating both contraction and relaxation. Further, testosterone maintains the structure of the 
corpus cavernosum. TRT is widely used to treat patients with testosterone deficiencies; how-
ever, the present discussion has also documented some problems associated with this therapeu-
tic approach. Basic research has also identified other potentially effective therapeutic methods 
for treating testosterone deficiency. Among these, PDE-5 inhibitors, L-citrulline, and resveratrol 
might be options for treating testosterone deficiency-induced ED. Future research should confirm 
these findings in more specific experiments that use molecular tools. Such additional research 
may shed more light on possible treatments for endocrine-mediated ED and its treatment.
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